Approaches to HTA in Europe, the USA, and elsewhere: Implications for patient access to current and future hemophilia treatments

Traditionally, the choice of drugs in developed countries has been driven by the views of patients and clinicians on the relative value of the available drugs. But increasingly, higher prices for novel and breakthrough drugs are focusing greater attention on determining the value for money spent, and health care systems, insurers and governments have all started to consider the affordability of drugs in their decision making.

In this afternoon’s “Medical: Health Technology Assessment” session, participants will see how health technology assessments (HTA) are the mechanism governments use to inform their decisions of whether to invest in or pay for a new drug or technology. While the pace of drug development for those living with bleeding disorders is accelerating, the use of HTAs is expanding globally a well. That means there is an increasingly urgent need to understand how HTAs work and how we as a community should be adjusting to these developments.

The interactive panel discussion will present both US and global perspectives on how HTAs operate and provide insights to inform us on what we should be preparing today to address future access and reimbursement challenges. It will also offer insight on current trends in health care and drug development that people involved in the community should be watching.


Photo credit: Maurizio De Angelis. Wellcome Images